Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SRPT
HOLDSarepta Therapeutics, Inc. · Healthcare · United States · $1.7B · Avg Vol: $58M/d
COMPANY DESCRIPTION
Sarepta Therapeutics, Inc. is a biopharmaceutical company focused on developing precision genetic medicines for rare neuromuscular diseases, particularly Duchenne muscular dystrophy (DMD). The company holds a leadership position in DMD therapeutics with multiple approved RNA-targeted and gene therapies, benefiting from strong intellectual property and orphan drug designations. Its specialized pipeline addresses significant unmet medical needs in ultra-rare conditions.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 933.0M | 1.2B | 1.9B | 2.2B | 33.1% | 2.2B | 1.8B | 1.4B | -20.0% |
| EPS | -8.03 | -5.80 | 2.47 | -7.13 | — | 0.34 | — | — | — |
| Shares | 88.0M | 93.7M | 96.9M | 105.0M | +19.3% | 105.6M | — | — | — |
| Debt | 1.6B | 1.4B | 1.3B | 1.0B | -13.7% | 1.0B | — | — | — |
| Equity | 384.9M | 859.3M | 1.5B | 1.1B | 43.6% | — | — | — | — |
| Op CF | -325.3M | -501.0M | -205.8M | -205.5M | — | 175.3M | — | — | — |
| Inv CF | -1.0B | -165.8M | 755.6M | 69.6M | — | — | — | — | — |
| Fin CF | 232.5M | 125.0M | 124.8M | -168.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SRPT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SRPT | Sarepta Therapeutics, Inc.(you) | $1.7B | 36 | HOLD |
| SEPN | Septerna, Inc. | $1.5B | 35 | HOLD |
| ADMA | ADMA Biologics, Inc. | $1.9B | 35 | SELL |
| NVAX | Novavax, Inc. | $1.2B | 36 | HOLD |
| BCAX | Bicara Therapeutics Inc. | $1.8B | 31 | SELL |
| VIR | Vir Biotechnology, Inc. | $1.5B | 32 | SELL |
| IOVA | Iovance Biotherapeutics, Inc. | $2.2B | 35 | HOLD |
| DMRA | Damora Therapeutics, Inc. | $1.8B | 30 | SELL |
| RAPP | Rapport Therapeutics, Inc. | $1.9B | 32 | SELL |
| SLS | SELLAS Life Sciences Group, Inc. | $2.2B | 38 | HOLD |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.7%